While FDA does not limit compounding to drug shortages and we believe there are paths to continue offering access to certain compounded GLP-1s after the shortage ends, we cannot guarantee that we will be able to continue offering these products in the same manner, to the same extent, or at all, due to a variety of factors outside our control, including supply chain, intellectual property, regulatory and resource allocation matters.) On October 2, 2024, this risk materialized when FDA announced on its website that Lilly had resolved the tirzepatide shortage, meaning that companies making and distributing compounded copies needed to stop in their tracks, regardless of ongoing patient care
The SS-31 peptide and other mitochondrial-targeted peptides are being studied for their cardiovascular protective properties
Batch traceability
GLP-1 microdosing refers to using a significantly lower dose of a GLP-1 medication than the FDA-approved schedule, often to minimize side effects while still achieving some metabolic benefit
It also functions as a nitrogen transporter between organs, supporting protein turnover and assisting in ammonia detoxification pathways
